Clascoterone Patent Expiration
Clascoterone is Used for treating acne vulgaris. It was first introduced by Sun Pharmaceutical Industries Ltd
Clascoterone Patents
Given below is the list of patents protecting Clascoterone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Winlevi | US8785427 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | Jul 25, 2030 | Sun Pharm |
| Winlevi | US9433628 | Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives | Feb 28, 2029 | Sun Pharm |
| Winlevi | US11207332 | Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives | Nov 20, 2028 | Sun Pharm |
| Winlevi | US10159682 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | Aug 14, 2028 | Sun Pharm |
| Winlevi | US11938141 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | Jul 24, 2028 | Sun Pharm |
| Winlevi | US9486458 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | Jul 24, 2028 | Sun Pharm |
| Winlevi | US8143240 | 17α, 21-dihydroxypregnene esters as antiandrogenic agents | Jan 12, 2026 | Sun Pharm |
| Winlevi | US8865690 | 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents | Jul 24, 2025 | Sun Pharm |
| Winlevi | US9211295 | 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents |
May 31, 2025
(Expired) | Sun Pharm |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Clascoterone's patents.
Latest Legal Activities on Clascoterone's Patents
Given below is the list recent legal activities going on the following patents of Clascoterone.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Interim Patent Term Extension Granted Critical | 22 May, 2024 | US8865690 |
| Interim Patent Term Extension Granted Critical | 22 May, 2024 | US9211295 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 May, 2024 | US9486458 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Mar, 2024 | US9433628 |
| transaction for FDA Determination of Regulatory Review Period | 14 Feb, 2024 | US9433628 |
| transaction for FDA Determination of Regulatory Review Period | 14 Feb, 2024 | US9486458 |
| transaction for FDA Determination of Regulatory Review Period | 14 Feb, 2024 | US9211295 |
| transaction for FDA Determination of Regulatory Review Period | 14 Feb, 2024 | US8865690 |
| transaction for FDA Determination of Regulatory Review Period | 14 Feb, 2024 | US8143240 |
| transaction for FDA Determination of Regulatory Review Period | 14 Feb, 2024 | US8785427 |
Clascoterone's Family Patents
